Fount of Information

InvivoGen社 Learn how InvivoGen supports AI drug screening




Artificial Intelligence in Drug Discovery


Technologies that utilize artificial intelligence (AI) have emerged to improve precision and speed up the time-consuming drug discovery phases. Many AI companies are thus partnering with pharma or biotech companies to help computationally screen through compound library and identify potential drug candidates. Here are a few examples of recent collaboration between AI companies and pharmas:



PRR Screening Service


Understanding the needs in AI-driven drug discovery, InvivoGen offers a high quality immunomodulatory compound screening service that can aid AI players in screening the compound library. Through validating the biological activities of compounds with cell-based assays, AI systems could narrow down the candidate choices and identify better molecules. Using our engineered HEK293 cells, compounds of interest can be tested for a panel of PRR ligands, including TLR, NOD1/2, RIG-I/ MDA-5, Dectin-1, Mincle and STING.

Screening Service Level 1


  • Compound Profiling
    Single dose testing on a set of PRRs

Screening Service Level 2


  • Compound Dose Response
    Dose response on one or several PRRs

SARS-CoV-2 Spike Pseudotyping Vectors

InvivoGen offers a collection of plasmids specifically designed for pseudotyping lentiviral particles with the full-length SARS-CoV-2 Spike (S) protein. These plasmids can also be used for screening of SARS-CoV-2 inhibitors including small molecules, monoclonal antibodies, or convalescent plasma.

Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。